17 juni 2024 USA
Diamyd Medical’s CEO Ulf Hannelius discusses Decoding the Future: Leveraging Biomarkers in Antigen-Specific Immunotherapy for Type 1 Diabetes.
The Sugar Science is an interactive digital platform founded to curate the scientific conversation among type 1 diabetes (T1D) researchers.
|